Application of G3BP1 ubiquitination inhibition therapeutic target in preparation of gastric cancer drugs

By binding hsa_circ_0000479 to G3BP1 and blocking the G3BP1-BTRC axis, the problem of insufficient therapeutic targets for gastric cancer was solved, which achieved inhibition of the proliferation and migration of gastric cancer cells and reduction of drug resistance, thus improving the prognosis of gastric cancer.

CN118976040APending Publication Date: 2024-11-19THE FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE (YIJISHAN HOSPITAL OF WANNAN MEDICAL COLLEGE)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411105860.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The lack of effective therapeutic targets for gastric cancer in existing technologies leads to poor treatment outcomes.

Method used

Using hsa_circ_0000479 as the therapeutic target, by binding to the G3BP1 protein, the hsa_circ_0000479-G3BP1-BTRC axis is blocked, thereby inhibiting the proliferation and migration of gastric cancer cells and reducing drug resistance.

Benefits of technology

It significantly inhibits the proliferation and migration of gastric cancer cells, reduces drug resistance, improves the prognosis of gastric cancer, and provides a new direction for targeted therapy of gastric cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976040A_ABST
    Figure CN118976040A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a treatment target for inhibiting G3BP1 ubiquitination in preparation of a medicine for treating gastric cancer, the treatment target is hsacirc0000479, and the sequence of the hsacirc0000479 is as shown in SEQ ID NO. 1, and the sequence of the hsacirc0000479 is as shown in SEQ ID NO. The hsacirc0000479 can be combined with the G3BP1 protein to control the invasion ability of gastric cancer cells in an in-vitro environment and an in-vivo environment. According to the invention, by blocking the expression of hsacirc0000479, the proliferation and migration capabilities of gastric cancer cells are inhibited, and the progress of gastric cancer is controlled; meanwhile, proliferation and migration of gastric cancer cells can be inhibited by blocking the hsacirc0000479-G3BP1-BTRC axis, and a new direction is provided for improving prognosis of gastric cancer and researching targeted therapy of gastric cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an application of inhibiting G3BP1 ubiquitination therapeutic target in preparing gastric cancer drugs. Background Art

[0002] Gastric cancer has always been a major public health problem that threatens human health. According to the latest data from the International Agency for Research on Cancer (IARC), gastric cancer (GC) ranks fifth in the world's new cancer cases with a proportion of 5.6%, and ranks fourth in cancer deaths with a proportion of 7.7%. Its age-standardized five-year net survival rate is generally between 20-40%.

[0003] Therefore, in order to improve the survival rate of cancer patients, many studies have shown that circRNA is involved in the malignant progression of cancer, for example, hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1 / TET1, thereby enhancing the DNA damage response of pancreatic ductal adenocarcinoma and promoting gemcitabine resistance. hsa_circ_0050386 inhibits the progression of non-small cell lung cancer by regulating the SRSF3 / FN1 axis.

[0004] However, since the early symptoms of gastric cancer are not obvious, most gastric cancer patients are diagnosed in the late stage. Although surgical methods and chemotherapy regimens have improved in recent years, the treatment of gastric cancer has not met expectations. Therefore, it is urgent to study new biomarkers and drug treatment targets for the diagnosis and prognosis of gastric cancer. Summary of the invention

[0005] The purpose of the present invention is to provide an application of a therapeutic target for inhibiting G3BP1 ubiquitination in the preparation of gastric cancer drugs, so as to solve the technical problem that it is difficult to propose a new therapeutic target for gastric cancer in the prior art.

[0006] In order to solve the above technical problems, the present invention specifically provides the following technical solutions:

[0007] The present invention provides an application of a therapeutic target for inhibiting G3BP1 ubiquitination in the preparation of a gastric cancer drug, wherein the therapeutic target is hsa_circ_0000479, and the sequence of hsa_circ_0000479 is the sequence shown in SEQ ID NO.1;

[0008] The hsa_circ_0000479 can control the invasive ability of gastric cancer cells in vitro and in vivo by binding to the G3BP1 protein.

[0009] As a preferred embodiment of the present invention, the hsa_circ_0000479 is highly expressed in GES-1 cells, MFC cells, H gastric cancer-27 cells, AGS cells, MKN-45 cells, and MKN-28 cells.

[0010] As a preferred embodiment of the present invention, the hsa_circ_0000479 promotes the progression of gastric cancer by competitively inhibiting the ubiquitination degradation of G3BP1 mediated by BTRC.

[0011] As a preferred embodiment of the present invention, the therapeutic drug includes an agent for inhibiting the therapeutic target;

[0012] The reagent includes primer 1, and the base sequence of the primer 1 is the sequence shown in SEQ ID NO.2.

[0013] As a preferred embodiment of the present invention, the reagent includes primer 2, and the base sequence of primer 2 is the sequence shown in SEQ ID NO.3.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] The present invention provides a therapeutic target hsa_circ_0000479, whose sequence is the sequence shown in SEQ ID NO.1. circ_0001479 is significantly upregulated in gastric cancer cells. By blocking the expression of hsa_circ_0000479, the proliferation and migration of gastric cancer cells can be inhibited, and the healing ability of gastric cancer cells can be reduced, the drug resistance of gastric cancer cells can be reduced, and the progression of gastric cancer can be controlled.

[0016] The present invention provides an hsa_circ_0000479-G3BP1-BTRC axis, which can inhibit the proliferation and migration of gastric cancer cells by blocking the hsa_circ_0000479-G3BP1-BTRC axis, thereby providing a new direction for improving the prognosis of gastric cancer and studying targeted treatment of gastric cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.

[0018] Figure 1 The present invention provides a schematic diagram of screening hsa_circ_0000479 in the GEO database as shown in Example 1;

[0019] Figure 2 Schematic diagram of the genomic location of hsa_circ_0000479 shown in Example 1 provided by the present invention;

[0020] Figure 3 Schematic diagram of the expression level detected by qRT-PCR between normal gastric mucosal cells and gastric cancer cell lines shown in Example 1 provided by the present invention;

[0021] Figure 4 Schematic diagram of the expression levels of hsa_circ_0000479 and mRNA detected by qRT-PCR in AGS and HGC-27 cells after RNase R treatment shown in Verification Example 1 provided by the present invention;

[0022] Figure 5 Schematic diagram of the RNA abundances of hsa_circ_0000479 and linear mRNA analyzed by qRT-PCR at different time points after actinomycin D treatment shown in Verification Example 1 provided by the present invention;

[0023] Figure 6 Detection chart of cell counting of gastric cancer cells AGS and MKN-45 in the control group and hsa_circ_0000479 knockdown group shown in Example 2 provided by the present invention;

[0024] Figure 7 Detection chart of the effect of hsa_circ_0000479 knockdown on the proliferation of gastric cancer cells AGS and MKN-45 determined by scratch test shown in Example 2 provided by the present invention;

[0025] Figure 8 Detection chart of EDU of the control group and hsa_circ_0000479 knockdown group in AGS and MKN-45 cells shown in Example 2 provided by the present invention;

[0026] Fig. 9 Detection chart of the Transwell experiment of the control group and hsa_circ_0000479 knockdown group in AGS and MKN-45 cells shown in Example 2 provided by the present invention;

[0027] Fig.10 Detection chart of Western Blot of EMT markers of the control group and hsa_circ_0000479 knockdown group shown in Example 2 provided by the present invention;

[0028] Fig.11 Cell counting chart of the control group and hsa_circ_0000479 overexpression group in gastric cancer cells HGC-27 and MKN-28 shown in Verification Example 2 provided by the present invention;

[0029] Fig.12This invention provides the detection graphs of the proliferation of gastric cancer cells HGC-27 and MKN-28 in the scratch test shown in Verification Example 2 for the hsa_circ_0000479 overexpression group;

[0030] Fig.13 This invention provides the EDU detection graphs of the control group and the hsa_circ_0000479 overexpression group in HGC-27 and MKN-28 cells shown in Verification Example 2;

[0031] Fig.14 This invention provides the detection graphs of the results of the Transwell experiment of the control group and the hsa_circ_0000479 overexpression group in HGC-27 and MKN-28 cells shown in Verification Example 2;

[0032] Fig.15 This invention provides the Western blot detection graphs of EMT markers for the control group and the hsa_circ_0000479 overexpression group shown in Verification Example 2;

[0033] Fig.16 This invention provides representative pictures of the subcutaneous xenograft tumors with hsa_circ_0000479 gene knockdown or overexpression shown in Verification Example 3;

[0034] Fig.17 This invention provides the tumor volume curves of the subcutaneous xenograft tumors with hsa_circ_0000479 gene knockdown or overexpression shown in Verification Example 3;

[0035] Fig.18 This invention provides the schematic diagrams of HE and Ki-67 IHC staining of the subcutaneous xenograft tumors with hsa_circ_0000479 gene knockdown or overexpression shown in Verification Example 3, original magnification 400×, scale bar = 50μm;

[0036] Fig.19 This invention provides the schematic diagrams of the FISH experimental results shown in Verification Example 4;

[0037] Fig. 20 This invention provides the result graphs of the expression levels of hsa_circ_0000479 in the nucleus and cytoplasm of AGS cells determined by qRT-PCR shown in Verification Example 4;

[0038] Fig.21 This invention provides the result graphs of the expression levels of hsa_circ_0000479 in the nucleus and cytoplasm of HGC-27 cells determined by qRT-PCR shown in Verification Example 4;

[0039] Fig. 22Provides a result graph of the RNA pull down experiment for finding the RBP protein of hsa_circ_0000479 as shown in Verification Example 4 for the present invention;

[0040] Fig.23 The present invention provides the characteristic peptide segment of G3BP1 shown in Verification Example 4;

[0041] Fig.24 The present invention provides validation example 4, as shown in Figure 4, the results of the precipitation of anti-G3BP1 antibody and hsa_circ_0000479 compared with the IgG control in AGS and H gastric cancer-27 cells, the relative enrichment (mean ± SD) represents the RNA level associated with G3BP1 relative to the control in three independent experiments, the data are expressed as mean ± SD, by unpaired Student's t test, ***P < 0.001;

[0042] Fig.25 The purpose of the present invention is to provide the Western blot detection results of G3BP1 protein when hsa_circ_0000479 is stably knocked out in AGS and MKN-45 cells as shown in Verification Example 5;

[0043] Fig.26 The present invention provides a Western blot detection result diagram of G3BP1 protein when hsa_circ_0000479 is overexpressed in H gastric cancer-27 and MKN-28 cells as shown in Verification Example 5;

[0044] Fig. 27 The present invention provides a graph showing the expression results of G3BP1 protein after AGS with stable knockout of hsa_circ_0000479 was treated with 26S protoplast inhibitor Mg132 as shown in Verification Example 5;

[0045] Fig.28 The present invention provides the results of G3BP1 protein expression after treating MKN-45 with stable knockout of hsa_circ_0000479 with the 26S protoplast inhibitor Mg132 as shown in Verification Example 5;

[0046] Fig.29 The present invention provides a schematic diagram of verification example 5, showing that treatment of H stomach cancer-27 with Mg132 can eliminate the expression of G3BP1 protein induced by hsa_circ_0000479;

[0047] Fig.30 A schematic diagram of the present invention is provided showing that treating MKN-28 with Mg132 can eliminate the G3BP1 protein expression induced by hsa_circ_0000479 as shown in Verification Example 5;

[0048] Fig.31The present invention provides a schematic diagram of verification example 5, which shows the result of treating gastric cancer cells with stable knockout of hsa_circ_0000479 and control cells with cycloheximide (CHX) for a period of time;

[0049] Fig.32 Provided is a result graph of treating gastric cancer cells overexpressing hsa_circ_0000479 and control cells with cycloheximide (CHX) for a period of time as shown in Verification Example 5 of the present invention;

[0050] Fig.33 Provides a Western blot result diagram of G3BP1 ubiquitination in cells stably silencing hsa_circ_0000479 or overexpressing hsa_circ_0000479 as shown in Verification Example 5 for the present invention;

[0051] Fig.34 The present invention provides a prediction map of the E3 ligase of G3BP1 predicted by the website shown in Verification Example 6;

[0052] Fig.35 The present invention provides a schematic diagram of the expression of G3BP1 protein in gastric cancer cells AGS and H gastric cancer-27 after knocking down BTRC as shown in Verification Example 6;

[0053] Fig.36 A schematic diagram of the interaction between BTRC and G3BP1 in gastric cancer cells as shown in Verification Example 6 is provided for the present invention;

[0054] Fig.37 A schematic diagram of the interaction between BTRC and G3BP1 after knocking down hsa_circ_0000479 in AGS and MKN-45 cells is provided for the present invention as shown in Validation Example 6;

[0055] Fig.38 A schematic diagram of the interaction between BTRC and G3BP1 after overexpression of hsa_circ_0000479 in H gastric cancer-27 and MKN-28 as shown in Verification Example 6 is provided for the present invention. DETAILED DESCRIPTION

[0056] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0057] The present invention provides a therapeutic target, wherein the therapeutic target is hsa_circ_0000479, and the sequence of hsa_circ_0000479 is the sequence shown in SEQ ID NO.1. The hsa_circ_0000479 isoform is in gene chr13:43528083-43544806-NM_033255375, and is cyclized from exon 2 to exon 6 of the EPSTI1 gene. The exons are connected end-to-end by reverse splicing to form a circRNA with a length of 275 nt (see Figure 2 ).

[0058] The present invention also provides two shRNAs (sh-1, sh-2) for stably knocking down the hsa_circ_0000479 reverse transcription site in gastric cancer cells, whose sequences are SEQ ID NO.2 and SEQ ID NO.3, respectively. After sh-1 and sh-2 are transfected into gastric cancer cells, respectively, they can inhibit the expression of hsa_circ_0000479, thereby controlling the development of gastric cancer.

[0059] It can be seen that hsa_circ_0000479 can be used in the preparation of drugs for the treatment of gastric cancer.

[0060] In the present invention, hsa_circ_0000479 was screened by the following examples:

[0061] Embodiment 1:

[0062] By analyzing the datasets GSE163416 and GSE17423 in the GEO database, a total of 241 differentially expressed circRNAs (Fold_change>2) were screened, of which 236 were in GSE163416 and 6 were in GSE174237. The results showed that hsa_circ_0000479 showed differences in both datasets (see Figure 1 ).

[0063] These results indicate that hsa_circ_0000479 is a potential circRNA candidate for regulating gastric cancer progression.

[0064] In addition, the expression of hsa_circ_0000479 (i.e., the above hsa_circ_0000479) was increased in gastric cancer cell lines GES-1 cells, MFC, H gastric cancer-27, AGS, MKN-45, and MKN-28 (see Figure 3 ).

[0065] All data in the figures *p≤0.05, **p≤0.01, ***p≤0.001 are presented as the mean ± SD of at least three independent experiments.

[0066] The following verifies that hsa_circ_0000479 is highly expressed in gastric cancer cells:

[0067] Verification Example 1:

[0068] (1) hsa_circ_0000479 has high stability:

[0069] RNA extracted from AGS and H gastric cancer-27 cells was treated with RNase R.

[0070] qRT-PCR results showed that RNase R reduced the expression of linear EPSTI1, but RNase R had little effect on hsa_circ_0000479 (see Figure 4 ).

[0071] (2) hsa_circ_0000479 has circular characteristics

[0072] AGS and H gastric cancer-27 cells were treated with the transcription inhibitor actinomycin D (ACTD) for different time periods.

[0073] The results are shown in the figure Figure 5 As shown, Figure 5 The mRNA levels of linear EPSTI1 gradually decreased over time, whereas the levels of hsa_circ_0000479 were more stable and resistant to actinomycin D treatment.

[0074] Through verification example 1, it can be seen that hsa_circ_0000479 is highly expressed in gastric cancer cells and has a more stable circular structure than the parental gene.

[0075] The following verification shows that hsa_circ_0000479 can inhibit the malignant progression of gastric cancer after knockdown:

[0076] Embodiment 2:

[0077] (1) Knockout of hsa_circ_0000479 inhibits gastric cancer cell proliferation

[0078] Two shRNAs (sh-1, sh-2) that stably knocked down the hsa_circ_0000479 reverse transcription site in gastric cancer cells were designed and transfected into gastric cancer cells AGS and MKN-45 with a control vector (sh-NC);

[0079] The CCK-8 assay was used to compare the proliferation curves of AGS and MKN-45 cells between the control group and the knockdown group.

[0080] Results Figure 6 As shown, knockout of hsa_circ_0000479 reduced cell proliferation in AGS and MKN-45 cell lines.

[0081] Perform EdU experiments, see the results Figure 8 It can be seen that downregulating hsa_circ_0000479 can significantly reduce the EdU positivity rate of gastric cancer cells.

[0082] (2) hsa_circ_0000479 regulates the migration of gastric cancer cells

[0083] Scratch assay was performed in six-well plates of AGS and MKN-45 cells transfected with stable knockdown of hsa_circ_0000479, and the percentage of wound healing was observed after 36 hours.

[0084] Results Figure 7 As shown, knocking out the expression of hsa_circ_0000479 significantly inhibited the wound healing of AGS and MKN-45 cells.

[0085] In this validation example, the Transwell migration assay was further used to evaluate the effect of hsa_circ_0000479 on the migration of gastric cancer cells.

[0086] Results Fig. 9 As shown, the migration ability of tumor cells transfected with shRNA was lower than that of cells in the control group.

[0087] (3) hsa_circ_0000479 mediates EMT phenotype

[0088] Given the central role of epithelial-to-mesenchymal transition (EMT) in regulating cancer metastasis, this validation example used Western Blot to detect the expression levels of EMT proteins E-Cadherin, N-Cadherin, Vimentin, and Snail.

[0089] Results Fig.10 When the expression of hsa_circ_0000479 was knocked down, the protein level of E-Cadherin in gastric cancer cells increased, while the expression of N-Cadherin, Vimentin and Snail decreased.

[0090] Example 2 shows that knocking down hsa_circ_0000479 has an inhibitory effect on the invasiveness of gastric cancer in vitro.

[0091] All data in the figures of Example 2 are expressed as mean±SD (n=3). *P<0.05, **P<0.01, ***P<0.001; scale bar=100 μm.

[0092] The following further verifies the effect of hsa_circ_0000479 on gastric cancer cells:

[0093] Verification Example 2:

[0094] In order to further verify the apparent function of hsa_circ_0000479, Verification Example 2 repeated the experiment of Example 2 above. The difference was that in Verification Example 2, an overexpression vector of hsa_circ_0000479 was constructed and transfected into gastric cancer cells H-27 and MKN-28.

[0095] (1) Overexpression of hsa_circ_0000479 enhances the proliferation ability of gastric cancer cells

[0096] Proliferation curves of gastric cancer cells transfected with overexpression vector and control vector were generated using CCK-8 assay, and the results are compared in Fig.11 , the growth rates of H gastric cancer-27 and MKN-28 cells overexpressing hsa_circ_0000479 were faster than those of control cells.

[0097] (2) Overexpression of hsa_circ_0000479 enhances the recovery ability of gastric cancer cells

[0098] Through EDU experiment, the results are shown in Fig.13 Overexpression of hsa_circ_0000479 can significantly increase the EdU positive rate of H gastric cancer-27 and MKN-28 cell lines. Further scratch test, the results are shown in Fig.12 Compared with the control group, overexpression of hsa_circ_0000479 could significantly promote wound closure in H gastric cancer-27 and MKN-28 cells.

[0099] (3) Overexpression of hsa_circ_0000479 enhances the migration ability of gastric cancer cells

[0100] Transwell migration assay was used to further confirm the results. Fig.14 Compared with the control group, gastric cancer cells overexpressing hsa_circ_0000479 showed stronger migration ability.

[0101] When hsa_circ_0000479 was overexpressed, the protein level of E-Cadherin in gastric cancer cells was decreased, while the expression of N-Cadherin, Vimentin, and Snail increased ( Fig.15 ).

[0102] Validation example 2 showed that overexpression of hsa_circ_0000479 has a tumor-promoting effect in gastric cancer and can enhance the malignant progression of gastric cancer cells in vitro.

[0103] All data are expressed as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001; scale bar = 100 μm.

[0104] The following validation examples further illustrate that hsa_circ_0000479 promotes tumorigenesis and development of gastric cancer cells in vivo

[0105] Verification Example 3:

[0106] To further evaluate the effect of hsa_circ_0000479 on gastric cancer cells in vivo, in this validation example, stable gastric cancer cells transfected with sh-1 and sh-2 and the corresponding negative control (sh-NC) were subcutaneously injected into BALB / cA nude mice. At the same time, a plasmid stably overexpressing hsa_circ_0000479 was transfected into gastric cancer cells.

[0107] The results show (see Figure 16-18 ):

[0108] (1) Compared with the control group, the tumor volume and Fig.18 ), in a subcutaneous tumor formation model study, hsa_circ_0000479 gene knockout strongly inhibited tumor growth in both cell lines.

[0109] (2) The tumor volume of the hsa_circ_0000479 gene overexpression group increased, that is, hsa_circ_0000479 gene overexpression can promote tumor growth in both cell lines.

[0110] (3) In immunohistochemistry (IHC) staining, it was also observed that the Ki-67 level in the hsa_circ_0000479 knockout group decreased ( Fig. 20 ), while the hsa_circ_0000479 overexpression group was the opposite.

[0111] The above results indicate that hsa_circ_0000479 can promote the occurrence and development of gastric cancer in vivo.

[0112] The therapeutic target hsa_circ_0000479 disclosed in the present invention can bind to G3BP1 and promote the occurrence of gastric cancer by inhibiting the ubiquitination of G3BP1, which is illustrated by several verification examples below.

[0113] Values ​​are expressed as mean ± SD; *P < 0.05, **P < 0.01 and ***P < 0.001.

[0114] Verification Example 4:

[0115] hsa_circ_0000479 is mainly localized in the cytoplasm and interacts with G3BP1 to promote the occurrence of gastric cancer

[0116] (1) Detection of the cellular localization of hsa_circ_0000479 in gastric cancer cells

[0117] Since the function of circRNA is usually related to its different localization in cells, this validation case detected the subcellular localization of hsa_circ_0000479 in gastric cancer cells by FISH ( Fig.19 ). Meanwhile, nuclear-cytoplasmic separation experiments were performed in AGS and H gastric cancer-27 cell lines.

[0118] The results are as follows Fig. 20 and Fig.21 As shown in the results, the expression of hsa_circ_0000479 in the cytoplasm was higher than that in the nucleus, indicating that hsa_circ_0000479 plays an important role at the transcriptional level.

[0119] (2) Verification of proteins related to hsa_circ_0000479 expression

[0120] Mass spectrometry analysis and RNA pull down experiments were performed to find the downstream proteins of hsa_circ_0000479.

[0121] like Fig. 22 As shown in the figure, the red arrows indicate differential protein bands with higher specificity and protein abundance, while the blue arrows indicate differential protein bands with weaker specificity and lower abundance. Then, among the differential protein bands with higher specificity, the protein with the highest score, Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) ( Fig.23 ).

[0122] RIP assay was performed, and the experimental results showed that the content of hsa_circ_0000479 in the RNA-protein complex precipitated by anti-G3BP1 antibody was significantly increased in gastric cancer cell lines AGS and H-Gastric Cancer-27 compared with the IgG control group ( Fig.24 ).

[0123] Therefore, hsa_circ_0000479 can bind to G3BP1 and participate in the progression of gastric cancer, that is, hsa_circ_0000479 participates in the progression of gastric cancer by binding to G3BP1.

[0124] The following verification example 5 further illustrates that hsa_circ_0000479 interacts with G3BP1 to participate in the progression of gastric cancer

[0125] Validation Example 5: hsa_circ_0000479 inhibits G3BP1 ubiquitination

[0126] (1) Western blot analysis showed that in AGS and MKN-45 cells, hsa_circ_0000479 knockdown significantly inhibited the expression of G3BP1 protein in gastric cancer cells compared with the control sh-NC cells ( Fig.25 ).

[0127] On the contrary, Fig.26 The results showed that overexpression of hsa_circ_0000479 significantly upregulated the protein level of G3BP1 in H gastric cancer-27 and MKN-28 cells ( Fig.26 ).

[0128] Since G3BP1 is highly expressed in multiple cancers and is involved in cancer progression through ubiquitination protein modification, hsa_circ_0000479 inhibits G3BP1 degradation through the ubiquitin-proteasome pathway.

[0129] (2) AGS and MKN-45 cells were treated with Mg132 (Mg132 is a known proteasome inhibitor that can inhibit the activity of intracellular proteases, thereby causing the accumulation of ubiquitinated proteins and promoting the ubiquitination process) (see Fig. 27 ), the results showed that the protein expression level of G3BP1 was significantly increased when hsa_circ_0000479 was knocked down compared with the control group.

[0130] In contrast, Mg132 inhibited the upregulation of G3BP1 protein induced by hsa_circ_0000479 in H-27 and MKN-28 cells (see Fig.28 , Fig.29 ), which demonstrated that hsa_circ_0000479 was involved in the regulation of G3BP1 proteasomal degradation.

[0131] (3) hsa_circ_0000479 affects the stability of G3BP1

[0132] Cycloheximide (CHX) is a new type of protein synthesis inhibitor. AGS and MKN-45 cells were treated with CHX, and the expression of G3BP1 protein was detected.

[0133] It was found that when hsa_circ_0000479 was knocked down, the expression of G3BP1 decreased. Compared with the control group, the decrease in the G3BP1 protein level in the hsa_circ_0000479 knockdown group was more rapid ( Fig.30 ).

[0134] After treating the gastric cancer cells HGC-27 and MKN-28 transfected with stable overexpression of hsa_circ_0000479 with CHX, the decrease rate of the G3BP1 protein level was significantly slower than that of the control group ( Fig.31 ).

[0135] (4) hsa_circ_0000479-dependent degradation of G3BP1 is mediated by ubiquitination

[0136] After immunoprecipitating the G3BP1 protein in AGS and MKN-45 cells transfected with HA-Ub, compared with the control group, a significant increase in the ubiquitination of the G3BP1 protein was detected in the cells with stable knockdown of hsa_circ_0000479 ( Fig.32 ). At the same time, consistent with the previous experimental results, the ubiquitination of G3BP1 was significantly reduced in the gastric cancer cells HGC-27 and MKN-28 with stable overexpression of hsa_circ_0000479 ( Fig.32 ).

[0137] The above results indicate that hsa_circ_0000479 regulates the expression of G3BP1 protein through the ubiquitin-proteasome pathway.

[0138] The following verification examples further illustrate that hsa_circ_0000479 promotes gastric cancer progression by competitively inhibiting the ubiquitination and degradation of G3BP1 mediated by BTRC

[0139] Verification Example 6: hsa_circ_0000479 blocks the binding of G3BP1 to the E3 ligase BTRC

[0140] (1) Predict the downstream E3 ubiquitin ligase of hsa_circ_0000479 through the website (http: / / ubibrowser.ncpsb.org.cn). The website prediction shows that there is only one E3 ligase, namely BTRC ( Fig.33 ).

[0141] In this validation example, Western blot experiments were performed to confirm whether BTRC is a novel E3 ligase of G3BP1. When BTRC expression was knocked down, the protein expression level of G3BP1 in AGS and H gastric cancer-27 cells was detected.

[0142] The results showed that when BTRC expression was knocked down, the protein level of G3BP1 in gastric cancer cells was significantly decreased compared with the control group ( Fig.34 ).

[0143] When anti-G3BP1 antibody was used to pull down BTRC in AGS and H-27 cells, Co-IP results showed that endogenous BTRC could be precipitated together with G3BP1 ( Fig.35 ).

[0144] When G3BP1 was pulled down using anti-BTRC antibody in AGS and HGC-27 cells, G3BP1 could bind to BTRC.

[0145] These results demonstrate that BTRC is a potential E3 ligase for G3BP1 in gastric cancer.

[0146] (2) Determine that hsa_circ_0000479 affects the interaction between G3BP1 and BTRC in gastric cancer cells

[0147] When AGS and MKN-45 cells were treated with Mg132, the expression of BTRC protein that could co-precipitate with G3BP1 was lower in hsa_circ_0000479 cells with stable knockdown compared with the control group ( Fig.37 ).

[0148] The results showed that when H-27 and MKN-28 cells were treated with Mg132, more BTR could co-precipitate with G3BP1 protein in cells stably overexpressing hsa_circ_0000479 compared with the control group ( Fig.38 ).

[0149] In summary, hsa_circ_0000479 can affect the binding of E3 ligase BTRC and G3BP1. It can be said that hsa_circ_0000479 controls the progression of gastric cancer by blocking the binding of G3BP1 and E3 ligase BTRC. Blocking the hsa_circ_0000479-G3BP1-BTRC axis can inhibit the proliferation and migration of gastric cancer cells, providing a new direction for improving the prognosis of gastric cancer and studying targeted treatment of gastric cancer.

[0150] The above embodiments are only exemplary embodiments of the present application and are not intended to limit the present application. The protection scope of the present application is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present application within the essence and protection scope of the present application, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present application.

Claims

1. An application of inhibiting G3BP1 ubiquitination therapeutic target in preparing gastric cancer drugs, characterized in that: The therapeutic target is hsa_circ_0000479, and the sequence of hsa_circ_0000479 is the sequence shown in SEQ ID NO.1; The hsa_circ_0000479 can control the invasive ability of gastric cancer cells in vitro and in vivo by binding to the G3BP1 protein.

2. The use according to claim 1, characterized in that: The hsa_circ_0000479 is highly expressed in GES-1 cells, MFC cells, H gastric cancer-27 cells, AGS cells, MKN-45 cells, and MKN-28 cells.

3. The use according to claim 1, characterized in that: The hsa_circ_0000479 promotes gastric cancer progression by competitively inhibiting G3BP1 ubiquitination degradation mediated by BTRC.

4. The use according to claim 1, characterized in that: The therapeutic agent includes an agent for inhibiting the therapeutic target; The reagent includes primer 1, and the base sequence of the primer 1 is the sequence shown in SEQ ID NO.

2.

5. The use according to claim 4, characterized in that: The reagent includes primer 2, and the base sequence of primer 2 is the sequence shown in SEQ ID NO.3.